A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Clinical trial NCT05732103 · RECRUITING

Trial details

NCT number: NCT05732103
Sponsor: Chordia Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Myelodysplastic Syndromes

Start date: 2023-04-25
Primary completion: 2028-06-01
Enrollment: 225

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.